Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00956345
First received: August 10, 2009
Last updated: July 4, 2012
Last verified: June 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2010
  Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
No publications provided by Novo Nordisk A/S

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):